Discover trends, market shifts, and competitive outlooks for the abrysvo or arexvy global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Abrysvo Or Arexvy Market Expected to Grow Between 2025 And 2029?

In recent times, the market size of abrysvo or arexvy has expanded at XX (HCAGR). The market, worth $XX million in 2024, is anticipated to escalate to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors such as the increasing elderly population, the start of immunisation schemes, heightened consciousness about respiratory diseases, governmental health campaigns, and sporadic respiratory disease epidemics have all contributed to this historical period of growth.

Expectations are high for the abrysvo or arexvy market, with a projected XX% forecast compound annual growth rate (FCAGR) in the next few years. By 2029, the market is anticipated to reach a value of $XX million, growing at a compounded annual growth rate (CAGR) of XX%. The forecasted growth can be attributed to factors such as the aging population, increased availability and global distribution of vaccines, a heightened emphasis on preventative healthcare, an uptick in cases of respiratory infections, and advancements in healthcare policies and coverage. Key trends promoting growth in the forecast period encompass advances in vaccine technology, personalized treatments, the integration of wearable health technology, innovations in vaccine delivery, enhancements in cold chain logistics, and the development of smart packaging.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

What are the Fundamental Drivers and Innovations Shaping the Abrysvo Or Arexvy Market?

The escalating occurrence of respiratory syncytial virus (RSV) infections is anticipated to fuel the expansion of the abrysvo or arexvy market. RSV infections, induced by the respiratory syncytial virus that primarily impacts the respiratory system, cause mild symptoms similar to common cold in most people but can cause severe sickness in babies, older individuals, and immunocompromised people. The contagion’s highly infectious nature, seasonal outbreaks, the lack of substantial immunity, and the heightened susceptibility among at-risk groups such as infants and the old age populace, amplify the occurrence of RSV infections. Abrysvo assists in tackling this increasing infection prevalence by offering specialized vaccines to safeguard high-risk groups, for instance, older individuals and infants, from acute respiratory syncytial virus-related diseases. For example, the Centers for Disease Control and Prevention, a health protection agency based in the US, stated that the total rate of hospitalizations linked with RSV touched 3.2 per 100,000 individuals during the 2024-25 season. Consequently, the occurrence of RSV infections is promoting the expansion of the abrysvo or arexvy market.

How Is the Abrysvo Or Arexvy Market Segmented?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=19948&type=smp

Which Regions Are Driving the Next Phase of the Abrysvo Or Arexvy Market Growth?

North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Trends Are Shaping the Future of the Abrysvo Or Arexvy Market?

In the market of abrysvo or arexvy, the primary trend centers around broadened age indications to expand the application of the vaccine across various age demographics, enhancing public health safety and enlarging market reach. The bivalent RSV prefusion F (RSVpreF) vaccine aims to provide immunity against the respiratory syncytial virus (RSV), covering both RSV-A and RSV-B subtypes. For example, in October 2024, Pfizer Inc., a pharmaceutical company in the US, received FDA clearance for ABRYSVO (RSV Vaccine), an RSVpreF vaccine, intended to prevent lower respiratory tract disease in adults aged 18 to 59 who are at a higher risk, thereby extending its indication to a more extensive adult population. It’s the only RSV vaccine endorsed for use in pregnant patients between 32 to 36 weeks of gestation to safeguard infants from birth up to six months.

View the full report here:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

How Is the Abrysvo Or Arexvy Market Defined and What Are Its Core Parameters?

Abrysvo (also known as arexvy) is a vaccine developed for the prevention of respiratory syncytial virus (RSV) in adults aged 60 and older. It is designed to reduce the risk of severe illness caused by RSV, which can lead to respiratory complications in older adults.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19948

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model